Back to Search
Start Over
1342P Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study.
- Source :
-
Annals of Oncology . 2020 Supplement 4, Vol. 31, pS861-S861. 1p. - Publication Year :
- 2020
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 31
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152696184
- Full Text :
- https://doi.org/10.1016/j.annonc.2020.08.1656